2 February 2021
Introducing the LUNA-FX7™ - the newest member of the award-winning LUNA™ Cell Counter family. The LUNA-FX7™ and the most powerful cell counter to date, with unmatched cell counting accuracy, new 1, 3 and 8-chamber slide options, state of the art optics, dual fluorescent and brightfield detection, precision autofocus, and 21 CFR PART 11 compliance. The LUNA-FX™ has built-in quality control features and precision validation slides for monitoring QC and production to help improve the efficiency and security of your lab s workflow. Download 10,000+
Hemostemix Inc.: Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects Follow-Up Visits at the End of March and Warrants Extended and Repriced
Hemostemix or the
Company ) is pleased to announce that all follow-up visits of the subjects enrolled in the HS 12 -01 clinical trial will be completed by March 31, 2021. A total 65 subjects who were enrolled in the trial, randomized 2:1 to receive ACP-01 or a placebo, will have completed the last follow-up appointments by March 31, 2021. The Company will provide additional information once trial data has been analyzed.
Warrant Amendments
The Company announces it is applying to the TSX Venture Exchange ( TSX-V ) for approval to amend the exercise price and expiration date of outstanding warrants (the
Hemostemix Inc.: Hemostemix Announces Private Placement Update
Hemostemix or the
Company ) announces that it was granted price protection of its previously announced non-brokered private placement of units (
Units ) announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the
Offering ). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of one post rollback common share in the capital of the Company (
Common Share ) and one post rollback common share purchase warrant (
Warrant ), with each full Warrant entitling the holder to acquire one Common Share at a price of $1.00 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.
Calgary, Alberta (Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed
Hemostemix Inc.: Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement
Hemostemix or the
Units ) for gross proceeds of $1,272,117.04 (the
Offering ). The Offering consisted of the issuance of an aggregate of 127,211,704 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company (
Common Share ) and one common share purchase warrant (
Warrant ), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.05 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below.